Regulus Therapeutics Inc. financial data

Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q1 2025 - 08 May 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1464% % 118%
Debt-to-equity 8% % -57%
Return On Equity -58% % 12%
Return On Assets -53% % 3.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 66,243,384 shares 1.2%
Common Stock, Shares, Outstanding 66,283,250 shares 1.2%
Entity Public Float $114,900,000 USD 319%
Common Stock, Value, Issued $66,000 USD 1.5%
Weighted Average Number of Shares Outstanding, Basic 66,174,550 shares 130%
Weighted Average Number of Shares Outstanding, Diluted 66,174,550 shares 130%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $36,146,000 USD 62%
General and Administrative Expense $15,606,000 USD 52%
Operating Income (Loss) $51,752,000 USD -59%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $47,522,000 USD -52%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $47,523,000 USD -52%
Earnings Per Share, Basic -1 USD/shares 53%
Earnings Per Share, Diluted -1 USD/shares 53%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $49,460,000 USD 67%
Cash, Cash Equivalents, and Short-term Investments $65,400,000 USD -39%
Other Assets, Current $1,087,000 USD -11%
Assets, Current $71,694,000 USD -29%
Property, Plant and Equipment, Net $1,121,000 USD 3.2%
Operating Lease, Right-of-Use Asset $1,988,000 USD 49%
Intangible Assets, Net (Excluding Goodwill) $23,000 USD -23%
Other Assets, Noncurrent $21,000 USD
Assets $74,826,000 USD -34%
Accounts Payable, Current $200,000 USD -51%
Employee-related Liabilities, Current $1,443,000 USD 22%
Accrued Liabilities, Current $808,000 USD 34%
Liabilities, Current $4,397,000 USD -23%
Operating Lease, Liability, Noncurrent $1,401,000 USD 61%
Liabilities $5,798,000 USD -11%
Accumulated Other Comprehensive Income (Loss), Net of Tax $10,000 USD
Retained Earnings (Accumulated Deficit) $569,205,000 USD -9.1%
Stockholders' Equity Attributable to Parent $69,028,000 USD -36%
Liabilities and Equity $74,826,000 USD -34%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $10,613,000 USD -21%
Net Cash Provided by (Used in) Financing Activities $45,000 USD -100%
Net Cash Provided by (Used in) Investing Activities $21,500,000 USD
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 66,283,250 shares 1.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $10,932,000 USD 88%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $49,522,000 USD 67%
Interest Paid, Excluding Capitalized Interest, Operating Activities $5,000 USD -89%
Deferred Tax Assets, Valuation Allowance $153,256,000 USD 9.3%
Deferred Tax Assets, Gross $153,617,000 USD 9.2%
Operating Lease, Liability $1,986,000 USD 24%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $47,468,000 USD -51%
Lessee, Operating Lease, Liability, to be Paid $2,478,000 USD 45%
Property, Plant and Equipment, Gross $5,521,000 USD 4%
Operating Lease, Liability, Current $585,000 USD -20%
Lessee, Operating Lease, Liability, to be Paid, Year Two $905,000 USD 227%
Lessee, Operating Lease, Liability, to be Paid, Year One $647,000 USD -21%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $492,000 USD 360%
Lessee, Operating Lease, Liability, to be Paid, Year Three $304,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $95,884,000 USD 3.5%
Unrecognized Tax Benefits $7,043,000 USD 13%
Lessee, Operating Lease, Liability, to be Paid, Year Four $0 USD
Depreciation, Depletion and Amortization $85,000 USD 4.9%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $8,999,000 USD 167%
Interest Expense $500,000 USD -30%